Wedbush Has Bullish Estimate for Immunome FY2024 Earnings

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Wedbush lifted their FY2024 earnings per share (EPS) estimates for shares of Immunome in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($2.11) for the year, up from their previous forecast of ($2.23). Wedbush currently has a "Outperform" rating and a $33.00 price objective on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.13) per share. Wedbush also issued estimates for Immunome's Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($2.70) EPS and FY2027 earnings at ($2.11) EPS.

Several other equities research analysts also recently issued reports on the stock. Piper Sandler cut their target price on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research note on Thursday. Stephens assumed coverage on Immunome in a research report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $28.83.

Immunome Trading Down 2.5 %

Shares of Immunome stock traded down $0.25 on Monday, reaching $9.66. 143,494 shares of the company were exchanged, compared to its average volume of 764,615. Immunome has a one year low of $6.93 and a one year high of $30.96. The company has a 50-day moving average of $13.12 and a 200 day moving average of $13.79. The company has a market capitalization of $602.98 million, a price-to-earnings ratio of -1.22 and a beta of 1.82.

Insider Transactions at Immunome

In other news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares of the company's stock, valued at approximately $760,090.76. This trade represents a 23.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 8.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Institutional investors have recently made changes to their positions in the stock. Quest Partners LLC acquired a new stake in Immunome in the 2nd quarter valued at $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome during the second quarter worth about $97,000. Arizona State Retirement System increased its position in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock worth $131,000 after acquiring an additional 918 shares in the last quarter. EntryPoint Capital LLC raised its holdings in shares of Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company's stock worth $136,000 after acquiring an additional 5,466 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock valued at $194,000 after acquiring an additional 4,129 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.